Sterling Biotech Limited reported unaudited standalone earnings results for the second quarter and six months ended September 30, 2018. For the quarter, the company's revenue from operations was INR 819.588 million compared to INR 897.978 million for the same period a year ago. Total income was INR 837.843 million compared to INR 920.252 million for the same period a year ago. Loss for the period was INR 1,361.300 million compared to INR 1,647.606 million for the same period a year ago. Basic loss per equity share was INR 5.01 against INR 6.05 for the same period a year ago. For the year to date, revenue from operations was INR 1,656.296 million compared to INR 1,905.446 million for the same period a year ago. Total income was INR 1,693.867 million compared to INR 1,942.192 million for the same period a year ago. Loss for the period was INR 24,453.313 million compared to INR 2,742.619 million for the same period a year ago. Basic loss per equity share was INR 142.02 against INR 10.01 for the same period a year ago.